Glooko Raises $ 30 Million Funding Round

New capital reflects the company’s growing trajectory and market growth

PALO ALTO, California, March 16, 2021 / PRNewswire / – Glooko inc., a leading provider of remote patient monitoring and chronic care management solutions, including diabetes and obesity, raised a $ 30 million Series D funding round. Funding was led by Health Catalyst Capital with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic. The proceeds will be used to accelerate organic growth and strategic initiatives across the company’s extensive and growing product line of advanced digital health solutions.

“Glooko has done a remarkable job bringing to market cutting-edge digital healthcare platforms, which enable people with diabetes to better manage their disease and improve their lives. This technology enables physicians to take better care of their lives. supports diabetes patients by strengthening engagement between people with diabetes and their health care providers, ”said Charles Boordy, Founder and Managing Partner of Health Catalyst Capital. “Through Glooko’s innovations, the company has experienced rapid market adoption, bringing its global ecosystem to more than 7,500 clinics and has partnered with many of the world’s largest diabetes medical device companies and corporations. pharmaceuticals, as well as with the best health systems. We look forward to supporting the company in its next phase of growth as it invests in new capabilities that support chronic care management and serve even more stakeholders. “

This round of funding follows a successful 2020 for Glooko, the most successful in its history despite the global pandemic. Over the past year, the company’s growth included key partnerships with major healthcare systems and extensive long-term existing partnerships with several leading global diabetes industry companies such as Insulet and Novo Nordisk.

The new product will accelerate the execution of Glooko’s business strategy, including increasing adoption of Glooko’s remote patient monitoring platform, expanding product commercialization in clinical research and expanding into additional therapeutic areas.

“This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this radical change. Glooko has experienced tremendous growth, and this funding allows us to leverage our strong momentum by providing the cutting-edge technologies for which we are known, “mentioned Russ johannesson, CEO of Glooko. “Today more than ever, the healthcare industry is looking for new, smarter technologies, whether for patient care or research into new therapies. I am thrilled to lead the Glooko team in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions. conditions with their healthcare professionals.

About Glooko
Glooko is transforming digital health by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research and enhanced collaboration. The company’s software platforms enable diabetes management by collecting and unlocking the power of data from blood glucose meters, CGMs, insulin pumps, pens and activity trackers, bringing information together into one place. Data is easily downloaded – remotely via an app or in the clinic, securely shared and visualized in actionable tables and graphs. This creates a solid foundation for confident collaboration and treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. More than 3 million users have benefited from diabetes data insight from Glooko’s solutions, trusted by global leaders in diabetes care, and used in 27 countries in 20 languages. Their US headquarters are located at Palo Alto, California with European headquarters in Gothenburg, Sweden. Learn more about glooko.com.

About Health Catalyst Capital
Health Catalyst Capital Management is an independent fund manager investing in private health information technology and technology services companies that seek to improve the human condition and promote value-based care. HCC was formed by a team of experienced healthcare investors and operators seeking profitable investment opportunities, while seeking to improve the human condition and promote value-based care.

Learn more about capitalcatalyseur.com.

Contacts:

Investors
Steve Lien
Chief Financial Officer, Glooko
+ 1650-720-5310

Media, North America
Tanya Rodante
Communications Director, Glooko
[email protected]
+1 415-608-5295

Media, Europe
Anders Sonesson
Managing Director EMEA / APAC, Glooko
[email protected]
+46735458888

SOURCE Glooko

Related links

http://www.glooko.com

About Georgia Duvall

Check Also

House panel leader vows to end “racial discrimination” at USDA

Sherrod said that despite the findings of discrimination in the Pigford case, there is no …

Leave a Reply

Your email address will not be published.